Osimo, Emanuele F. http://orcid.org/0000-0001-6239-5691
Sweeney, Mark
de Marvao, Antonio
Berry, Alaine http://orcid.org/0000-0001-6049-4418
Statton, Ben http://orcid.org/0000-0001-5118-7977
Perry, Benjamin I. http://orcid.org/0000-0002-1533-026X
Pillinger, Toby http://orcid.org/0000-0002-6074-2626
Whitehurst, Thomas http://orcid.org/0000-0002-7005-902X
Cook, Stuart A.
O’Regan, Declan P.
Thomas, E. Louise http://orcid.org/0000-0003-4235-4694
Howes, Oliver D. http://orcid.org/0000-0002-2928-1972
Funding for this research was provided by:
DH | National Institute for Health Research
RCUK | Medical Research Council (MC-A656-5QD30)
British Medical Association
Article History
Received: 4 November 2021
Revised: 17 November 2021
Accepted: 23 November 2021
First Online: 6 December 2021
Competing interests
: SAC is a co-founder and director of Enleofen Bio PTE LTD, a company that develops anti-IL-11 therapeutics. Enleofen Bio had no involvement in this study. ODH is a part-time employee of H Lundbeck A/s. He has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angelini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati, Roche, and Viatris/Mylan. ODH has a patent for the use of dopaminergic imaging. DPO’R has received grant funding from Bayer AG. None of these had any involvement in this study. TP has participated in educational speaker meetings organised by Lundbeck, Otsuka, Sunovion, Schwabe Pharma, and Recordati. All other authors report no conflicts of interest.